Dyne Therapeutics (NASDAQ:DYN) Upgraded at Jones Trading

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) was upgraded by research analysts at Jones Trading to a "strong-buy" rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

A number of other analysts have also recently weighed in on the stock. Oppenheimer started coverage on shares of Dyne Therapeutics in a research note on Monday, June 2nd. They set an "outperform" rating and a $34.00 target price on the stock. Scotiabank started coverage on Dyne Therapeutics in a research report on Friday, March 7th. They set a "sector outperform" rating and a $50.00 price objective on the stock. Evercore ISI assumed coverage on Dyne Therapeutics in a report on Thursday, May 29th. They issued an "outperform" rating and a $46.00 target price for the company. JPMorgan Chase & Co. dropped their target price on Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating for the company in a research report on Friday, March 21st. Finally, Sanford C. Bernstein started coverage on Dyne Therapeutics in a research note on Tuesday. They set a "market perform" rating and a $13.00 price target on the stock. One investment analyst has rated the stock with a sell rating, two have given a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $41.13.

Dyne Therapeutics Stock Down 3.6%

NASDAQ:DYN opened at $10.05 on Wednesday. Dyne Therapeutics has a twelve month low of $6.36 and a twelve month high of $47.45. The stock's 50-day simple moving average is $11.80 and its 200 day simple moving average is $14.08. The firm has a market capitalization of $1.14 billion, a PE ratio of -2.80 and a beta of 1.16.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($1.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.17). On average, analysts anticipate that Dyne Therapeutics will post -3.44 EPS for the current fiscal year.

Institutional Investors Weigh In On Dyne Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in DYN. Caitong International Asset Management Co. Ltd lifted its stake in Dyne Therapeutics by 378.6% in the first quarter. Caitong International Asset Management Co. Ltd now owns 3,092 shares of the company's stock valued at $32,000 after buying an additional 2,446 shares during the period. Quarry LP acquired a new stake in shares of Dyne Therapeutics during the 1st quarter worth approximately $47,000. GF Fund Management CO. LTD. bought a new stake in shares of Dyne Therapeutics in the 4th quarter valued at $50,000. E Fund Management Co. Ltd. lifted its position in shares of Dyne Therapeutics by 16.2% during the 1st quarter. E Fund Management Co. Ltd. now owns 13,771 shares of the company's stock valued at $144,000 after acquiring an additional 1,923 shares during the period. Finally, Optimize Financial Inc bought a new position in Dyne Therapeutics during the first quarter worth $154,000. Institutional investors own 96.68% of the company's stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.